Verrica Pharmaceuticals (VRCA) to Release Earnings on Tuesday

Verrica Pharmaceuticals (NASDAQ:VRCA) will likely be announcing its Q1 2025 earnings results after the market closes on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $2.53 million for the quarter.

Verrica Pharmaceuticals (NASDAQ:VRCA) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.01. The firm had revenue of $0.34 million for the quarter, compared to analyst estimates of $1.30 million. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%. On average, analysts expect Verrica Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Verrica Pharmaceuticals Stock Up 6.0%

VRCA opened at $0.44 on Monday. The firm has a market cap of $40.68 million, a price-to-earnings ratio of -0.24 and a beta of 1.73. Verrica Pharmaceuticals has a fifty-two week low of $0.38 and a fifty-two week high of $11.41. The company’s 50-day moving average price is $0.51 and its 200 day moving average price is $0.72.

Institutional Investors Weigh In On Verrica Pharmaceuticals

A hedge fund recently raised its stake in Verrica Pharmaceuticals stock. Bank of America Corp DE raised its position in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) by 347.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 143,818 shares of the company’s stock after purchasing an additional 111,678 shares during the quarter. Bank of America Corp DE owned about 0.32% of Verrica Pharmaceuticals worth $101,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 42.45% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on VRCA. Needham & Company LLC reiterated a “hold” rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, April 9th. HC Wainwright reiterated a “neutral” rating on shares of Verrica Pharmaceuticals in a research note on Tuesday, April 8th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $9.50.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.